Benzinga
Benzinga
Benzinga
martes, septiembre 29

Lifecore Biomedical Inc

LFCRNASDAQ
Trade with Public
Trade with Public
$6.59
0.071.07%
al cierre: Sep 29, 5:00 PM EST
$6.58
-0.01-0.15%
After hour: 6:19 PM EST
PRO
¿Por qué se mueve?:Lifecore Biomedical shares are trading higher after the company announced t...
Fusiones y adquisiciones: Lifecore Biomedical (LFCR) announced it will be acquired by Webster Equity Partners on Monday, September 28, 2026 for $663.7M paid in cash
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Lifecore Biomedical Financials

Lifecore Biomedical (LFCR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from
Benzinga Newsdesk

PRO
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.
Benzinga Newsdesk

PRO
Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses of $(0.53) per share
Benzinga Newsdesk

PRO
CORRECTION: Lifecore Biomedical Q4 EPS $(0.16) Up From $(0.20) YoY, Sales $35.747M Down From $37.886M YoY

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 percent increase over losses of $(0.20) per share from the same period last year. The company reported $35.747 million in
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved